Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
Authors
Keywords
-
Journal
EUROPEAN HEART JOURNAL
Volume 41, Issue 36, Pages 3402-3418
Publisher
Oxford University Press (OUP)
Online
2020-06-11
DOI
10.1093/eurheartj/ehaa496
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
- (2020) Matteo Serenelli et al. JACC-Heart Failure
- A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
- (2019) John J.V. McMurray et al. EUROPEAN JOURNAL OF HEART FAILURE
- Target Doses of Heart Failure Medical Therapy and Blood Pressure
- (2019) Poghni A. Peri-Okonny et al. JACC-Heart Failure
- The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics
- (2019) John J.V. McMurray et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
- (2018) Ulrik M. Mogensen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Medical Therapy for Heart Failure With Reduced Ejection Fraction
- (2018) Stephen J. Greene et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- (2018) Bryan Williams et al. EUROPEAN HEART JOURNAL
- Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
- (2017) Michael Böhm et al. EUROPEAN HEART JOURNAL
- Observations on the blood pressure paradox in heart failure
- (2017) Hector O. Ventura et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN HEART JOURNAL
- Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
- (2015) C David Sjöström et al. Diabetes & Vascular Disease Research
- Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT
- (2014) Michel Komajda et al. EUROPEAN JOURNAL OF HEART FAILURE
- Response to Ryan and Parwani: Heart Failure Patients With Low Blood Pressure: How Should We Manage Neurohormonal Blocking Drugs?
- (2012) Biykem Bozkurt Circulation-Heart Failure
- Effect of Baseline and Changes in Systolic Blood Pressure Over Time on the Effectiveness of Valsartan in the Valsartan Heart Failure Trial
- (2008) Inder S. Anand et al. Circulation-Heart Failure
- Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure
- (2008) C E Raphael et al. HEART
- Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program
- (2008) Peter A. Meredith et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More